Brief: GenFleet Therapeutics (Shanghai) Says GFH375 Combined With Cetuximab Placed On Proposed BTD List
22/09/2026 02:42
BRIEF-GenFleet Therapeutics (Shanghai) Says GFH375 Combined With Cetuximab Placed On Proposed BTD List Sept 22 (Reuters) - GenFleet Therapeutics (Shanghai) Inc 2595.HK:
GFH375 COMBINED WITH CETUXIMAB PLACED ON PROPOSED BREAKTHROUGH THERAPY DESIGNATION LIST BY NMPA ON SEP 18
Further company coverage: 2595.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GenFleet Therapeutics (Shanghai)
See all newsHK-listed GenFleet jumps on positive progress of cancer drug
GenFleet hits over 3-week high as cancer drug makes progress on BTD list
Brief: GenFleet Therapeutics (Shanghai) Says GFH375 Combined With Cetuximab Placed On Proposed BTD List
HK-listed GenFleet rises most in a month on repurchasing shares
Brief: GenFleet Therapeutics (Shanghai) Reports Loss Of RMB220.17 Million For Six Months